Study details
Enrolling now
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Ebrahim S Delpassand
NCT IDNCT06972628ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 3.9 years
Ages
18+
Sex
Male only
Locations
1 site in TX
What this study is about
This trial is testing a treatment called Lutetium-177-PSMA-617 (PLUVICTO) in men with advanced prostate cancer that has spread to the bones. The goal is to see if PLUVICTO is safe and well-tolerated for these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Administering Lutetium-177-PSMA-617 (PLUVICTO)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Overall Survival, Radiographic progression-free survival
Body systems
Oncology